Kadmon Holdings Inc (NASDAQ:KDMN) CFO Konstantin Poukalov bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The shares were acquired at an average cost of $5.81 per share, with a total value of $23,240.00. Following the completion of the purchase, the chief financial officer now owns 1,000 shares of the company’s stock, valued at $5,810. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kadmon Holdings Inc (NASDAQ:KDMN) opened at 6.37 on Wednesday. Kadmon Holdings Inc has a 1-year low of $4.44 and a 1-year high of $10.48. The firm’s market cap is $287.15 million. The firm has a 50-day moving average of $6.28 and a 200 day moving average of $7.86.

Kadmon Holdings (NASDAQ:KDMN) last issued its earnings results on Wednesday, November 9th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $3.83. The firm had revenue of $5.70 million for the quarter, compared to the consensus estimate of $3.90 million. The business’s revenue for the quarter was down 49.6% on a year-over-year basis. Analysts expect that Kadmon Holdings Inc will post ($10.63) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Several hedge funds and other institutional investors have recently modified their holdings of KDMN. KCG Holdings Inc. acquired a new position in shares of Kadmon Holdings during the third quarter valued at about $102,000. California State Teachers Retirement System purchased a new position in Kadmon Holdings during the third quarter valued at $126,000. BlackRock Institutional Trust Company N.A. purchased a new position in Kadmon Holdings during the third quarter valued at $129,000. Omega Advisors Inc. purchased a new position in Kadmon Holdings during the third quarter valued at $679,000. Finally, Beach Point Capital Management LP purchased a new position in Kadmon Holdings during the third quarter valued at $1,480,000.

KDMN has been the subject of several recent research reports. Jefferies Group reissued a “buy” rating and set a $10.00 target price (down from $12.00) on shares of Kadmon Holdings in a research note on Thursday, November 10th. Citigroup Inc. began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They set a “neutral” rating and a $12.00 price target on the stock. JMP Securities began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They set an “outperform” rating and a $16.00 price target on the stock. WBB Securities began coverage on shares of Kadmon Holdings in a report on Monday, August 1st. They set a “sell” rating and a $7.50 price target on the stock. Finally, HC Wainwright began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They set a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Kadmon Holdings currently has a consensus rating of “Hold” and a consensus price target of $14.10.

About Kadmon Holdings

Kadmon Holdings, Inc, formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

5 Day Chart for NASDAQ:KDMN

Receive News & Stock Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related stocks with our FREE daily email newsletter.